SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending due to its impending addition to the S&P 500, sparking debate about its high valuation and business practices. While some celebrate the stock's impressive run, others argue it's a sign of market corruption and an opportunity for insiders to offload shares, with many anticipating a significant correction after its inclusion.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

TREASURE GLOBAL INC ($TGL) is trending due to a massive surge following its reverse stock split, sparking discussions of a potential short squeeze. Community members are actively comparing it to similar plays like $SMX and debating whether it will continue its upward trajectory. The stock's low float and high volatility are also key points of discussion among traders.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Despite a massive volume spike, NFLX is trending down, driven by concerns surrounding a potential acquisition of Warner Bros. Discovery and the significant debt it could incur. The community is debating the merits of the deal, with some seeing it as a strategic move to dominate streaming, while others fear regulatory hurdles and financial strain.

What is the project about? Vara Network is a substrate-based future proof smart contract platform that is fast, scalable, and makes it simple to create and deploy next-generation Web3.0 dApps Vara is the first standalone network in the Gear Protocol  Gear is a next-gen cloud infrastructure platform providing most intuitive and frictionless environment for web2 and web3 developers to build complex infrastructure solutions and disruptive dApps for any ecosystem  What makes your project unique? Vara is built upon three core concepts: The actor model, and persistent memory — two widely adopted primitives from massive computation and microservices architecture spaces  Wasm — a WebAssembly-based virtual machine that runs on all modern browsers. Proven to be faster than any alternative web2 virtual machines  Vara was created to serve as a wasm-native hub for innovative protocols that leverage parallel execution and asynchronous programming to deliver leading decentralized products in any segment  History of your project. Gear Protocol and the Vara Network were originally created by Nikolay Volf, one of the core developers of Polkadot. In 2021, he embarked on building an advanced layer 1 smart contract platform using Substrate, Polkadot's custom framework. His vision included creating a platform that enables fast and efficient execution of robust, feature-rich dApps while in a seamless development environment similar to that of Web 2.0 development. He did this by  harnessing the power of innovative technologies like Wasm, the Actor Model, and Persistent Memory. These technologies significantly enhance smart contract development and provide a seamless end-user experience and provide the foundation for the development of Vara Network.  1. Q2 2021 - Pre-Seed Round: In the second quarter of 2021, the Protocol secured its initial funding through a pre-seed round. This likely involved seeking investment from early-stage investors or venture capitalists to kickstart the development of the project.  2. Q4 2021 - Seed Round: In December 2021 raised $12 Million in Venture Round. Private investment round led by Blockchange Venture. In addition to Blockchange, other top venture capital funds participated in this round, including Three  Arrows Capital, Lemniscap, Distributed Global, LAO, Mechanism Capital, Bitscale, Spartan Group LLC, HashKey, DI Ventures, Elysium Venture Capital, Signum Capital and P2P Economy lead by Konstantin Lomashuk, along with a number of top executives of Web3 Foundation and Parity Technologies. Dr. Gavin Wood, Founder and ex-CEO of Parity Technologies and one of the key individual investors participating in this round.  3. 2022 - Intensive Scaling and Development, First Test Integrations: Throughout the year 2022, Vara was focused on two primary activities. First, the engagement in an extensive outreach process to build up the team. Second, the project advanced its technical development efforts and started working on integrating their technology with various test environments to ensure its functionality and viability.  4. Q4 2022 - Testnet Launch.   5. Q1 2023 - PoA Launch: In the first quarter of 2023, Vara achieved launch of its Proof of Authority (PoA) consensus network, which is a chain candidate for mainnet.  Current Status of Vara:  Presently, the project boasts a talented and diverse decentralized workforce, consisting of dozens of engineers and other community members  to drive the project's success.  One of the remarkable aspects of Vara is its substantial pipeline of initiatives with over 40 projects.  What’s next for your project? Current projects being researched and developed by the community:  - Intensive testing and improvement of the actor model features in the blockchain space  - Launch of the key stack of dApps in our parallel and asynchronous environment   - Development of innovative infrastructure solutions (e.g offchain zk actors including machine learning) independently and together with the segment leaders  What can your token be used for? VARA tokens maintain core utility features required for the network to operate: transaction fees staking and network security governance other: gas pools for gas reservation  Contributors to the Gear protocol are exploring the mechanics of how to distribute a portion of block rewards directly toward dApp developers

Vara Network

Vara Network is trending as traders discuss its potential, citing its low market cap and availability on Coinbase as key factors.  The community is actively debating its long-term prospects, weighing its potential as a layer-1 solution against concerns about tokenomics and past performance. Staking rewards and the upcoming Ethereum bridge are also sparking interest, though opinions on the project's legitimacy remain divided.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to community excitement around its low float and recent news, with many traders actively discussing potential for a significant price surge similar to other low-float runners. Chatter suggests the stock's momentum may continue, although caution is advised due to risks associated with low-float stocks.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy ($TE) is trending following news of a partnership with Corning to produce 'Made in America' solar panels and a multi-year $75M+ solar frame deal with Nextracker. Community members are bullish, citing the company's potential to benefit from policy tailwinds and growing demand for renewable energy to power AI data centers, though some remain cautious due to past financial performance and upcoming earnings.

Wheeler Real Estate Investment Trust, Inc. engages in the acquisition, finance, development, lease, ownership, and management of retail properties. Its property portfolio includes income producing, strip centers, neighborhood, grocery-anchored, community, and free-standing retail properties. The company was founded on June 23, 2011 and is headquartered in Virginia Beach, VA.

Wheeler Real Estate Investment Trust Inc

WHLR is trending due to significant intraday volatility and a massive surge in trading volume, reminiscent of other recent low-float runners like $SMX and $TGL. The community is actively discussing potential short squeezes, dilution concerns, and price targets, while weighing the company's fundamentals against its speculative potential. Some traders believe WHLR could see substantial gains, citing its small float and asset value, while others are wary of potential share dumping.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending due to an 8K filing indicating plans to submit a PDUFA application after the SOL-1 readout, signaling confidence in positive data and a potentially faster path to market. The community speculates this assertive move suggests strong trial data, with some anticipating a significant stock surge. Discussions also involve comparing OCUL to competitors and speculating on potential acquisition scenarios in the ophthalmology sector.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics is trending as traders discuss its low float and potential for a short squeeze, drawing comparisons to other high-flying stocks. Some are pointing to recent filings while others are looking at technical indicators, anticipating a significant price movement. Community members are sharing alerts, discussing potential price targets, and highlighting the stock's increasing volume.

Stitch Fix, Inc. engages in the provision of personalized shipments of apparel, shoes, and accessories. Its main sections are men's, kids, petite, maternity, and plus apparels. The company was founded by Katrina Lake and Erin Morrison Flynn in February, 2011 and is headquartered in San Francisco, CA.

Stitch Fix Inc - Ordinary Shares - Class A

Stitch Fix Inc

Stitch Fix is trending due to a positive revenue outlook and better-than-expected earnings, sparking discussions about a potential turnaround and the impact of AI-driven personalization. The community is analyzing revenue growth metrics and the company's cash position, while some remain skeptical about active client numbers and long-term profitability. KeyBanc Capital Markets Consumer Conference on December 12, 2025, is also adding to the buzz.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

Shares of SpringWorks Therapeutics Inc. ended over 9% higher on Thursday following a report that the company is inching closer to getting acquired by an established giant, triggering a jump in discussions among retail traders.During regular trading hours on Thursday, The Wall Street Journal reported that Merck KGaA is nearing a $3.5 billion deal to acquire SpringWorks, which specializes in rare diseases and cancer.The report, citing people familiar with the matter, noted that the German giant had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-jumps-ahead-of-q4-2024-report/ch5uuz0RwZ">confirmed</a> in February that it was in advanced talks for the buyout, and the two parties have now agreed on a price close to $47 per share.After the closing bell, Merck <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.eqs-news.com/news/ad-hoc/merck-kgaa-merck-confirms-late-stage-discussions-with-springworks-therapeutics-inc-on-potential-acquisition/b6bde507-964a-46d9-846d-9d15390345d9_en">confirmed</a> the report, saying the two parties were discussing a deal at around $47 per share. However, it added that they had neither made any final decision nor entered into a legally binding agreement.On Stocktwits, sentiment for SpringWorks jumped into the 'extremely bullish' zone, accompanied by a 657% spike in message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SWTX_sentiment_and_message_volume_as_of_April_24_png_712d46db30.webp" alt="SWTX sentiment and message volume as of April 24.png" width="1318" height="316"><figcaption>SWTX sentiment and message volume as of April 24. | source: Stocktwits</figcaption></figure>Several watchers appeared dissatisfied with the offer, indicating some alignment with the after-hours dip on Thursday."$47 is a joke, surely?" wrote one user, adding that Pfizer should throw its hat into the ring of prospective buyers.<stembedurl>https://stocktwits.com/monoksop/message/612643957</stembedurl>However, others expressed some relief."What I get, I get. Won't be super happy or anything, but I'll take the W and move on," said one watcher.<stembedurl>https://stocktwits.com/Son_of_Shango/message/612642003</stembedurl>SpringWorks has garnered interest from suitors thanks to its lead asset, Gomekli, which treats a rare genetic disorder that causes tumor growth in nerve tissue.The company's first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. It raked in $61.5 million in the fourth quarter of 2024.<a href="https://stocktwits.com/symbol/SWTX">SpringWorks' stock</a> has gained over 23% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.

Equity

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.


SpringWorks Therapeutics springs higher as Merck KGaA takeover said close

Investing.com -- Shares of  SpringWorks Therapeutics Inc  (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close.

Mineralys Therapeutics Inc. (123% jump in watchers)The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data from its Phase 3 and Phase 2 trials for lorundrostat in treating uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). Both trials met their primary efficacy endpoints, showing statistically significant blood pressure reductions.&nbsp;The company also announced a $250 million underwritten public offering to fund lorundrostat’s development and pre-commercialization efforts.Mineralys stock is up over 15% year-to-date (YTD).Tenaya Therapeutics Inc. (11% jump in watchers)Tenaya saw increased attention after reporting stronger-than-expected fourth-quarter earnings and highlighting upcoming clinical data readouts for its gene therapy programs targeting cardiomyopathies.&nbsp;CEO Faraz Ali noted continued progress in the TN-201 MyPEAK-1 and TN-401 RIDGE-1 trials.&nbsp;Tenaya’s stock remains down over 53% YTD.SpringWorks Therapeutics Inc. (10% jump in watchers)SpringWorks gained traction amid ongoing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-sees-biggest-weekly-biotech-jump-in-stocktwits-following/cheUZARRbb2">speculation</a> about a potential buyout by Merck KGaA. While Merck confirmed advanced merger discussions in its annual report, it stopped short of announcing a deal, leaving traders searching for clues. The company’s withdrawal from a Barclays healthcare conference further fueled speculation.&nbsp;SpringWorks stock is up more than 40% YTD.COSCIENS Biopharma Inc. (9% jump in watchers)COSCIENS initiated a Phase 2a clinical efficacy trial for its avenanthramides product, which is being explored for its anti-inflammatory properties. The trial, dubbed the AvenActive study, will assess safety and efficacy in two dosage arms.&nbsp;COSCIENS stock has gained over 20% YTD.Metagenomi Inc. (7% jump in watchers)Metagenomi published new research in Nature Communications on its novel CAST gene editing system, which enables precise, programmable integration of large gene cargoes. The technology could have major implications for treating genetic diseases like cystic fibrosis and Duchenne Muscular Dystrophy.&nbsp;Metagenomi stock is down more than 46% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.  

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even as its shares tumbled more than 14%, marking their worst weekly decline since mid-January.&nbsp;Despite the drop, retail sentiment flipped to 'bullish' from 'neutral,' driven by renewed speculation about German healthcare giant Merck KGaA (MKGAY) confirming details about a buyout.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_March_10_cba5133a09.png" alt="SWTX sentiment and message volume March 10.png" width="1316" height="302"><figcaption>SWTX sentiment and message volume March 10. | source: Stocktwits</figcaption></figure>According to The Fly, Barclays analyst Peter Lawson noted that some investors had anticipated confirmation of an acquisition from Merck's earnings report last week.&nbsp;However, Merck's annual report, published Thursday, only acknowledged that discussions about a potential merger were at an advanced stage but stated that there was no certainty a deal would be signed.&nbsp;The absence of a definitive announcement left traders analyzing the language for clues.Adding to speculation, SpringWorks canceled its planned appearance at Barclays' healthcare conference this week, continuing a pattern of event withdrawals following the FDA approval of its lead drug, Gomekli, for treating neurofibromatosis type 1 (NF1).&nbsp;The company had previously backed out of an earnings call and another public event, fueling investor theories that a significant corporate development was underway.&nbsp;Barclays maintained an 'Overweight' rating on SpringWorks, with a price target of $63. It sees limited regulatory risk to a potential Merck buyout.Retail traders on Stocktwits reacted strongly to these developments. Message volumes surged, and the company's follower count increased by 17.9%, the highest among all biotech stocks last week.&nbsp;Some investors speculated that an acquisition could be announced this week, with one suggesting a potential offer price of $120 per share — a 140% premium to SpringWorks' last closing price.&nbsp;<stembedurl>https://stocktwits.com/Aombeus/message/607327621</stembedurl>Another pointed to Merck not disclosing a termination of negotiations, which German law would have allegedly required if talks had ended, and reaffirmed their belief in SpringWorks' leadership.<stembedurl>https://stocktwits.com/TheGunnerAB/message/607292647</stembedurl>According to Koyfin, short interest in SpringWorks has declined from 15.7% at the start of the year to 12.2% last week, suggesting that bearish bets against the stock have been easing.&nbsp;The company's shares currently trade at a 47% discount to the average analyst price target of $72.88. Five of the eight analysts covering SpringWorks have a ‘Buy’rating, while three rate it a ‘Strong Buy,’ according to Koyfin.Despite last week's sharp decline, SpringWorks remains up more than 36% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor optimism ahead of its quarterly earnings report due after the next session.The biopharmaceutical company, focused on treatments for rare diseases and cancer, is expected to report a narrowing of fourth-quarter (Q4) adjusted losses to $0.71 per share from $1.44 a year earlier.&nbsp;Meanwhile, revenue is projected to soar to $57.16 million from $5.4 million.On Stocktwits, sentiment remained firmly bullish, though message volumes dipped slightly.The stock’s retail following grew over 2% in the past week and more than 26% in the past month.Users noted that after-hours trading volumes spiked well above the daily average, signaling heightened interest.<stembedurl>https://stocktwits.com/patten1962/message/604919223</stembedurl>One trader posted: “Yet another sleepless night ahead. I hope this is the last, and we can all celebrate.”<stembedurl>https://stocktwits.com/StrangerTrades/message/604917416</stembedurl>Recent investor enthusiasm has been fueled by&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-soars-on-acquisition-buzz/ch5EgKYRtu">reports</a> that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks. While no official confirmation has been made, there are hopes that a potential deal could be signed in the coming weeks.Last week, BofA Securities raised its price target on SWTX to $87 from $65, maintaining a Buy rating. The research firm cited FDA approval for SpringWorks’ lead asset, Gomekli, as a key growth driver.Gomekli, a MEK inhibitor, treats neurofibromatosis type 1 (NF1), a rare genetic disorder that causes tumor growth in nerve tissue.In addition, SpringWorks’ first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. Last month, the company pre-announced Q4 U.S. Ogsiveo sales of $61.5 million.Despite the bullish momentum, short interest on SpringWorks stock climbed from 15.7% at the start of the year to 19.4% last week, according to Koyfin data.Still, SWTX shares have surged over 53% year-to-date, far outpacing the S&amp;P 500’s 4.7% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over SpringWorks Therapeutics and Jewelry...

Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation drove heavy trading.&nbsp;The stock is on track for its best day on record following a Reuters report that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company, according to people familiar with the matter.&nbsp;If discussions are successful, a deal could be signed in the coming weeks, though neither Springworks nor Merck have commented on the report yet.Springworks is a commercial-stage biopharmaceutical company developing treatments for severe rare diseases and cancer.&nbsp;Ogsiveo, the company's first FDA-approved therapy, is used in the U.S. to treat adult patients with progressing desmoid tumors who require systemic treatment.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_Feb_10_3b1f0e47dd.png" alt="SWTX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>SWTX sentiment and message volume Feb 10 as of 12:10 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Springworks was 'extremely bullish' as message volume spiked, pushing the stock into the list of top trending symbols by late Monday morning.&nbsp;Retail traders flooded the platform with congratulatory messages for long-term holders, though some warned that a sharp pullback could occur if official statements refute the buyout rumors.<stembedurl>https://stocktwits.com/flanker30/message/603597464</stembedurl><stembedurl>https://stocktwits.com/AngusMacbeth/message/603598578</stembedurl>Last month, Springworks pre-announced fourth-quarter U.S. Ogsiveo sales of $61.5 million, exceeding TD Cowen's $57.0 million estimate and consensus expectations of $59.8 million. The brokerage had suggested that a buyout could be on the horizon.Springworks stock has risen 16% over the past 12 months. According to Koyfin data, its short interest stood at 18.4% as of the last check.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

Springworks surges as Germany's Merck KGaA said to be targeting takeover

Investing.com -- Shares of Springworks Therapeutics (NASDAQ:SWTX) surged over 37% on Monday following reports that Germany’s  Merck  (NSE:PROR) KGaA is in advanced talks to acquire the U.S. biotech company, according to Reuters.

SpringWorks Therapeutics Stock Gets A RS Rating Lift

SpringWorks Therapeutics Stock Gets A RS Rating Lift...

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

SpringWorks Therapeutics Inc

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

SWTX
SpringWorks Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SWTX News

SWTXSpringWorks Therapeutics Inc